Literature DB >> 20579325

Cystosonographic measurements of canine bladder tumours.

C Hume1, G Seiler, Y Porat-Mosenco, A Caceres, F Shofer, K Sorenmo.   

Abstract

The purpose of this study was to evaluate the variability of cystosonographic bladder tumor measurements with both operator and bladder volume changes. Ten dogs with bladder tumors were included. In each dog, three operators determined tumor dimensions for three different bladder volumes. Intraclass correlation coefficient was used to assess operator reliability. Response Evaluation Criteria in Solid Tumors (RECIST) and greater than or equal to 50% differences in tumor measurements were used as guidelines. Poor to fair correlations between operators were found for the different tumor dimensions (r(I) = 0.4 - 0.7). The percent differences in tumor dimensions with operator and bladder volume changes were significant enough to misclassify the tumors into the categories of partial response (PR) or progressive disease (PD). These results suggest that cystosonographic measurements of bladder tumors are affected by both changes in operator and bladder volume, and the discrepancies are significant enough to change response classification.

Entities:  

Mesh:

Year:  2010        PMID: 20579325     DOI: 10.1111/j.1476-5829.2010.00212.x

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  7 in total

1.  Chemotherapy and radiation therapy in 4 dogs with muscle-invasive transitional cell carcinoma of the urinary tract.

Authors:  Laura Marconato; Dagmar B Nitzl; Katja J Melzer-Ruess; Marcel A Keller; Julia Buchholz
Journal:  Can Vet J       Date:  2012-08       Impact factor: 1.008

2.  Canine urinary bladder transitional cell carcinoma tumor volume is dependent on imaging modality and measurement technique.

Authors:  Andrew J Leffler; Eric T Hostnik; Emma E Warry; Gregory G Habing; Danelle M Auld; Eric M Green; Wm Tod Drost
Journal:  Vet Radiol Ultrasound       Date:  2018-07-10       Impact factor: 1.363

3.  Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.

Authors:  Noah M Hahn; Patty L Bonney; Deepika Dhawan; David R Jones; Curtis Balch; Zhongmin Guo; Corie Hartman-Frey; Fang Fang; Heidi G Parker; Erika M Kwon; Elaine A Ostrander; Kenneth P Nephew; Deborah W Knapp
Journal:  J Urol       Date:  2011-11-17       Impact factor: 7.450

4.  Presumptive malignant transformation of chronic polypoid cystitis into an apical transitional cell carcinoma without BRAF mutation in a young female dog.

Authors:  Emmanuelle Marie Butty; Shelley Hahn; Mary Anna Labato
Journal:  J Vet Intern Med       Date:  2021-03-19       Impact factor: 3.333

5.  Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.

Authors:  W T N Culp; C Weisse; A C Berent; J A Reetz; E L Krick; D E Jackson; P H Kass; C A Clifford; K U Sorenmo
Journal:  J Vet Intern Med       Date:  2015-04-21       Impact factor: 3.333

6.  Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs.

Authors:  S D Allstadt; C O Rodriguez; B Boostrom; R B Rebhun; K A Skorupski
Journal:  J Vet Intern Med       Date:  2015-01       Impact factor: 3.333

7.  A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.

Authors:  Sarah B Rippy; Heather L Gardner; Sandra M Nguyen; Emma E Warry; Roberta A Portela; William Tod Drost; Eric T Hostnik; Eric M Green; Dennis J Chew; Juan Peng; Cheryl A London
Journal:  BMC Vet Res       Date:  2016-11-17       Impact factor: 2.741

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.